11-13 January Sala Giolitti, Centro Congressi Torino Incontra via Nino Costa 8. Turin, Italy

Transcription

1 11-13 January 2012 Sala Giolitti, Centro Congressi Torino Incontra via Nino Costa 8 Turin, Italy

2

3 7th Residential Course on Clinical Pharmacology of Antiretrovirals Course Director Prof. G. Di Perri Department of Infectious Diseases, University of Turin, Italy. Course Scientific Secretary Prof. S. Bonora Department of Infectious Diseases, University of Turin, Italy Phone: / , Fax: , stefano.bonora@unito.it Organizing Secretary HealthData Consulting S.r.l. Via Morghen, 27 Torino - Italy Phone Fax segreteria@hdcons.it

4 COURSE DESCRIPTION The effectiveness of Highly Active Antiretroviral Therapy (HAART) has dramatically changed the life expectancy of HIV-positive individuals. In last years, availability of new drugs and new classes of compounds led to increase therapeutical choices for HIV patients. However, drug development in this field has been particularly rapid, and many issues related to long-term drug efficacy and safety have still to be evaluated in the clinical setting. Moreover, focus on individual needs of HIV patients according to genetic, demographical and clinical characteristics, suggested by a modern viewpoint of management of this longlife treatment, emphasizes the need of personalization and optimization of the regimens. Under this viewpoint, knowledge of clinical pharmacology of antiretrovirals seems crucial for a modern approach to HIV therapy. A proper use of drugs according to pharmacokinetic and pharmacodynamic properties can maximize the benefits and limit the drawbacks of the treatment. AIM OF THE COURSE The aim of the 3-day course is to address the clinicians to a correct management of antiretroviral therapy based on a sound and comprehensive evaluation of the PK/PD characteristics of antiretroviral drugs. The course contents will consist of lectures, clinical case' presentations, roundtables and plenary discussions in order to stimulate confrontation and improve understanding of critical issues. TARGET AUDIENCE Healthcare professionals who routinely take care of patients with HIV infection. FACULTY M. Andreoni, Department of Infectious Diseases, University Tor Vergata, Rome, Italy. A. Antinori, Department of Infectious Diseases, IRCCS Lazzaro Spallanzani, Rome Italy. J. Arribas, Autonoma University School of Medicine, Madrid, Spain. D. Back, Department of Pharmacology & Therapeutics, University of Liverpool, UK. M. Boffito, Pharmacokinetic Research Unit, Chelsea and Westminster Hospital, London, UK. S. Bonora, Department of Infectious Diseases, University of Turin, Italy. N. Bumpus, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

5 D. Burger, Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands. A. Calcagno, Department of Infectious Diseases, University of Turin, Italy. P. Cinque, Infectious Diseases Unit, Fondazione Centro S. Raffaele Monte Tabor - H.S. Raffaelele, Milan, Italy. A. D'Avolio, Department of Infectious Diseases, University of Turin, Italy. G. Di Perri, Department of Infectious Diseases, University of Turin, Italy. C. V. Fletcher, Departments of Clinical Pharmacy and Pharmaceutical Sciences, and Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, USA. C. Flexner, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. M. Galli, Department of Infectious Diseases, University of Milan, Italy. R. Garraffo, Pharmacology Laboratory, CHU Pasteur, Nice France. V. Ghisetti, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy. D. González de Requena Farré, Department of Infectious Diseases, University of Turin, Italy. A. Gori, Infectious Diseases Unit, A.O. San Gerardo, Monza, Italy. A. Hill, Pharmacology Research Laboratories, University of Liverpool, UK. S. Khoo, Department of Pharmacology & Therapeutics, University of Liverpool, UK. M. Kurowski, Department of Immunodeficiency Diseases, Ludwig Maximilians University, Berlin, Germany. M. Lamorde, Research Department, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. A. Lazzarin, Infectious Diseases Unit, Fondazione Centro S. Raffaele Monte Tabor - H.S. Raffaelele, Milan, Italy. C. La Porte, Clinical Investigation Unit - Pharmacokinetic Laboratory, Faculty of Medicine, University of Ottawa, Canada. S. Letendre, Department of Medicine, University of California San Diego, La Jolla, CA, USA. A. M. Mills, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. J. Moltò, University Hospital Germans Trias i Pujol, Barcelona, Spain. A. Novelli, Department of Preclinical and Clinical Pharmacology, University of Florence, Italy. A. Owen, Department of Pharmacology & Therapeutics, University of Liverpool, UK. C. F. Perno, Virology Unit, University Tor Vergata, Rome, Italy. M. Rizzetto, Department of Gastroenterology, University of Turin, Italy. M. Siccardi, Department of Infectious Diseases, University of Turin, Italy.

6 11 JANUARY TH 11 JANUARY AFTERNOON SESSION (Chairpersons: G. Di Perri, V. Ghisetti) Welcome, introduction and pre-test (G. Di Perri) Glossary and Principles of Clinical Pharmacology (A. Novelli) Why a clinician should be interested in clinical pharmacology of ARVs? (S. Khoo) PK, genetic barrier and resistance (M. Andreoni) Coffee break Integration of resistance and PK data: a clinical viewpoint (J. Molto) Pharmacological mechanisms of antiretrovirals toxicity I (D. Gonzalez de Requena) A pharmacological reading of clinical trials (G. Di Perri) 12 JANUARY TH 12 JANUARY MORNING SESSION (Chairman: M. Kurowski) 9.00 PK variability beyond genes (C. Fletcher) 9.30 Roundtable: Dose optimization and personalization: where are the opportunities? (Discussants: G. Di Perri, C. Flexner, C. Fletcher) - A pharmacokinetic viewpoint (A. Hill) - A pharmacogenetic viewpoint (A. Owen) - New pharmacological tools for dose optimization? (M. Siccardi) - A clinical viewpoint (S. Bonora) Which role for clinical pharmacology in developing countries? (M. Lamorde)

7 AFTERNOON SESSION (Chairman: R. Garraffo) Basic technical aspects and organization of a TDM service (A. D'Avolio) Clinical scenarios for TDM use (C. La Porte) Drug-drug interactions: old problems and new challenges (D. Burger) Priorities and pitfalls in the management of drug-drug interactions(s. Bonora) Coffee break Clinical cases presentation Roundtable: Clinical pharmacology of HIV: a lesson for anti-hcv therapy? (Discussant: M. Rizzetto) - New anti-hcv agents: a pharmacological perspective (C. Flexner) - Clinical pharmacology of ribavirin (G. Di Perri) 13 JANUARY RD 13 JANUARY MORNING SESSION (Chairman: A. Gori) 8.30 Pharmacological mechanisms of antiretroviral toxicity II (N. Bumpus) 9.00 Pharmacology of prevention (D. Back) 9.30 Roundtable: A journey to the CNS (Discussant: P. Cinque) - Pharmacology of ARVs in CNS (A. Calcagno) - More insight into the penetration and activity of ARVs (S. Letendre) - Neuropenetration of ARVs: the clinical viewpoint (A. Antinori) - Search and destroy HIV in SNC: the virological viewpoint (C.F. Perno) Clinical cases presentation AFTERNOON SESSION (Chairman: M. Galli) New drugs and new Single Tablet Regimens: clinical and pharmacological perspectives (A. Mills) Roundtable: Less Drug Regimens: is HAART changing face? (Discussant: G. Di Perri) - Less Drug Regimens in guidelines and in practice ( A. Lazzarin) - What we have learned from clinical studies (J. Arribas) - Clinical pharmacology of Less Drug Regimens (M. Boffito) Final test

8 COURSE LOCATION Sala Giolitti, Centro Congressi Torino Incontra via Nino Costa 8 HOW TO REACH THE COURSE VENUE - Highway access: A5 Torino-Ivrea-Aosta (Alps tunnels Gran San Bernardo, Mont Blanc) A6 Savona-Ligurian Riviera A21 Piacenza-Bologna-Firenze A32 Torino-Bardonecchia-Frejus - International airport: Caselle distance from the Conference Centre: 15 Km. - Railway station: Porta Nuova distance from the Conference Centre: 1 Km. - Railway station: Porta Susa distance from the Conference Centre: 2.2 Km.

9 REGISTRATION INCLUDES - Admission to all course sessions - Name tag - Satchel - Free onsite wireless for attendee use - Catering as per below Please see what meals are included with your registration below: DAY Wednesday th 11 January Thursday th 12 January BREAKFAST Not included Not included MORNING BREAK Not included Friday rd 13 January Not included LUNCH Welcome coffee AFTERNOON BREAK DINNER National Museum of the Italian Risorgimento * Not included * The Course offers to all the attendees of the event a Social Dinner in the exclusive venue of the National Museum of the Italian Risorgimento, Palazzo Carignano, via Accademia delle Scienze, Turin. The Museum can be reached on foot (5 min walk) from the Course centre. Social dinner is free of charge for participants, but is essential to confirm your presence. In confirming your participation, let us know if you require a vegetarian meal, or if you have any food intollerance or allergies.

10 TRAVEL AGENCY Course participants will be contacted by BTA Bird Travel Agency (Ms Paola Comandini) in order to arrange their transfers and hotel accomodation. BTA Bird Travel Agency S.r.l., p.le Caduti della Montagnola 65 - Rome, phone , mail: birdtravel.magliana@libero.it HOTEL ACCOMODATION Hotel Victoria via Nino Costa 4, Turin, Italy phone fax A number of rooms have been pre-booked for course participants. The registered participants will be contacted by the Organizers for transfer and hotel accomodation.

11 NOTES

12 Diamond Sponsor Gold Sponsor Silver Sponsor